Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Portland, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 400,000 people, planned
- Started
- 26 Sept 2022
- Expected to end
- 30 Sept 2027
- Type of study
- Observational, 4 groups
- Record updated
- 2 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (5)Hide the full registry criteria
Who can take part
- Phase 1:
- Veterans with a laboratory-confirmed positive test for SARS-CoV-2 or a diagnosis of COVID-19 documented at any time since the beginning of the pandemic in January 2020 to present; Phase 2:
- All Veterans alive and in Veterans Health Administration (VHA) care as of January 2018
- Specific exclusion/inclusion criteria and observation periods will be further defined for each sub-study (See outcomes/publications)
Who cannot take part
- VA employees who are not enrollees
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Rsv or influenza
This trial is currently available in United States.
- VA Portland Health Care System, Portland, ORPortland, United StatesContact: Kristina L Bajema, MDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to comprehensively describe the temporal and geographic utilization of COVID-19 therapies used for mild to moderate disease during different periods of SARS-CoV-2 variant circulation as well as to compare demographic and clinical characteristics of Veterans who are treated or do not receive these different therapies. The investigators will also perform similar descriptive epidemiology for other respiratory viruses, including RSV and influenza and other infectious diseases. This first phase will critically inform feasibility and direction of the second phase, in which the investigators will use target trial emulation design to study the comparative effectiveness of therapies and vaccines for COVID-19, respiratory viruses, including RSV, and influenza, and other infectious diseases.
The 4 groups in the trial
- Outpatient Veterans with risk factors for severe COVID-19 & tested positive during Jan-Feb 2022
This cohort study assessed outpatient Veterans with risk factors for severe COVID-19 who tested positive for SARS-CoV-2 during January and February 2022. The purpose is to describe factors associated with receipt of outpatient COVID-19 pharmacotherapies in the Veterans Affairs (VA) health care system.
- Nonhospitalized Veterans in VHA at risk for SARS-CoV-2 Jan-Jul 2022
Three retrospective target trial emulation studies comparing matched cohorts of nirmatrelvir-ritonavir versus no treatment, molnupiravir versus no treatment, and nirmatrelvir- ritonavir versus molnupiravir. The purpose is to measure the effectiveness of nirmatrelvir-ritonavir and molnupiravir for outpatient treatment of COVID-19.
- Outpatient Veterans who tested positive for SARS-CoV-2 from Jan 2022 through Jan 2023
This cohort study evaluated nonhospitalized Veterans in VHA care who tested positive for SARS-CoV-2 from January 2022 through January 2023 using VHA and linked Community Care and Medicare databases. The purpose is to analyze trends and factors associated with prescription of outpatient COVID-19 pharmacotherapies within the Veterans Health Administration (VHA).
- Outpatient Veterans with risk factors for severe COVID-19 & tested positive during Jan-Jul 2022
Retrospective target trial emulation study comparing matched cohorts receiving nirmatrelvir-ritonavir versus no treatment. The purpose is to measure the effectiveness of outpatient treatment of COVID-19 with nirmatrelvir-ritonavir in preventing Post COVID conditions.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- CSP #2038 - COVID-19 Pharmacotherapy Effectiveness in the VA Healthcare System (COPE-VA)
- Criteria questions
- Built from NCT06160128, who can take part
- Record updated
- 2 November 2026